

ASX RELEASE

Appendix 4D

In accordance with Listing Rule 4.2A, please find attached the Half-Year Appendix 4D for the half-year ended 30 September 2016.

It is recommended that the half-year reports be read in conjunction with the Annual Report for the year ending 31 March 2016 and any public announcements made by the company during the half-year.

ASX Appendix 4D

Half-Year Report 30 September 2016

Name of Entity	Volpara Health Technologies Limited (the "Company")
ARBN	609 946 867
Reporting Period	30 September 2016
Previous Corresponding Reporting Period	30 September 2015

Results for announcement to the market

	6 Months to 30 September 2016 Unaudited NZ\$'000	6 Months to 30 September 2015 Unaudited NZ\$'000	Amount (NZ\$'000) and Percentage Change
Revenue from ordinary activities	1,228	1,172	56 (4.8%)
Operating deficit	(4,771)	(1,464)	(3,307) (226%)
Net loss before tax	(4,675)	(2,069)	(2,606) (126%)
Net loss after tax	(4,675)	(2,069)	(2,606) (126%)

Dividends

Nil.

Net tangible assets

Net tangible assets backing per ordinary share (NZ\$0.04) (six months to 30 September 2015: NZ\$0.14).

In anticipation of the initial public offering and listing in April 2016, the Company undertook a share split of 3:1. The effect of this share split has been incorporated into the calculation of per share amounts for all periods presented.

Details of associate and joint venture entities

None.

Details of entities over which control has been gained or lost during the period

No entities were acquired during the period. No entities were disposed of due to loss of control during the period.

Note:

The information provided in this Appendix 4D is based on the Volpara Health Technologies Limited Interim Financial Report for the financial half-year ended 30 September 2016.

Volpara Health Technologies Limited Interim Financial Report for the financial half-year ended 30 September 2016 has been subject to review by the Company auditors. A copy of the Independent Review Report is included in the Interim Financial Report.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. It launched its cloud-based *VolparaEnterprise™* solution which incorporates objective breast density assessment with a range of automated quality control features focused on improving quality and productivity in July 2016.

www.volparasolutions.com